Corbus Pharmaceuticals Holdings, Inc. current report, 25 May 2017

Abrir documento

Business Context and Reporting Period

This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on May 25, 2017. The filing documents corporate governance actions taken at the Company's Annual Meeting of Stockholders held on the same date. The Company is an emerging growth company incorporated in Delaware.

Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and voting results.

Material Changes

Effective May 25, 2017, the Company implemented significant changes to its governance structure following stockholder approval:

  • Amended and Restated Certificate of Incorporation: Filed with the Delaware Secretary of State to eliminate the ability of stockholders to act by written consent and to eliminate the ability of stockholders to call special meetings.
  • Amended and Restated Bylaws: Adopted by the Board of Directors to align with the Certificate amendments, similarly removing stockholder rights to act by written consent or call special meetings.

Outlook, Management Commentary, and Voting Results

The filing details the results of five proposals voted upon at the Annual Meeting:

  1. Election of Directors: All five nominees (Dr. Yuval Cohen, Alan Holmer, David P. Hochman, Dr. Renu Gupta, and Avery W. Catlin) were elected. Each received over 31 million votes "For" with approximately 10.8 million broker non-votes.
  2. Elimination of Written Consent: Approved with 29,345,422 votes "For" and 1,834,946 votes "Against."
  3. Elimination of Special Meetings: Approved with 29,034,385 votes "For" and 2,148,974 votes "Against."
  4. Adoption of Restated Certificate: Approved with 29,233,658 votes "For" and 1,768,628 votes "Against."
  5. Ratification of Auditors: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017, was overwhelmingly approved with 41,796,976 votes "For" and 215,025 votes "Against."

The filing does not provide specific management commentary on future business outlook, risks, or contingencies beyond the procedural updates.

Key Facts for Investor Verification

  • Stockholders have lost the ability to act by written consent or call special meetings effective May 25, 2017.
  • The Board of Directors and the five named directors were re-elected or confirmed for one-year terms.
  • EisnerAmper LLP was ratified as the independent auditor for the 2017 fiscal year.
  • Broker non-votes were significant (approx. 10.8 million) for director elections and governance proposals but did not affect the outcome of the votes.
  • Exhibits 3.1 and 3.2 contain the full text of the Amended and Restated Certificate of Incorporation and Bylaws.